Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Should l Buy ?
Source: Globenewswire
Company Developments: Inhibikase Therapeutics reported a net loss of $13.7 million for Q1 2025 and is preparing to initiate a Phase 2b clinical trial for its PAH treatment, IKT-001, in the second half of 2025, following the refinement of its study protocol with experts.
Leadership Changes and Financial Overview: The company appointed new executives including Mark Iwicki as CEO and reported significant increases in R&D expenses due to its acquisition of CorHepta, while maintaining a cash position of $93.2 million as of March 31, 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
